Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to find the highest dose of the investigational drug XL092 that can be given safely with immunotherapy drugs in people with advanced solid tumors that have come back or continued to grow despite treatment. Immunotherapy drugs boost the ability of the immune system to find and kill cancer cells.
Researchers want to find the best dose of BMS-986504 to use safely in people with lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their tumors are missing the MTAP gene.
People with endometrial cancer often gain weight during and after chemotherapy. Medicines to reduce the risk of an allergic reaction for people receiving chemotherapy can also raise blood sugar. Weight gain can affect overall health and cancer recovery.
Researchers want to learn if AMG 193 in combination with standard treatment is safe for people with advanced pancreatic cancer. The people in this study have pancreatic ductal adenocarcinoma (PDAC) that has metastasized (spread). In addition, their cancers have a mutation (change) in the MTAP gene. This results in a lack of the MTAP protein, which may help cancer grow.
Researchers are comparing taletrectinib with a placebo (inactive drug) in people with non-small cell lung cancer (NSCLC). The people in this study have stage 1B-3A NSCLC that has a ROS1 gene fusion. They have had the tumor completely removed with surgery.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
In this study, researchers want to see if enzalutamide, alone or with mifepristone, works well against advanced breast cancer. The people in this study have either triple-negative breast cancer (TNBC) or cancer that is low in estrogen receptors (ER). Receptors are docking sites on cancer cells for hormones or other proteins. TNBC is breast cancer that is not fueled by estrogen or progesterone and does not make a protein called HER2. The people in this study also have cancer cells that have receptors for proteins called androgens (AR-positive cancers).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are comparing three different treatments for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment. If you join this study, you will be randomly assigned to get one of these treatments:
